{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:38:28Z","timestamp":1767137908504,"version":"build-2238731810"},"publisher-location":"Cham","reference-count":204,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319571911","type":"print"},{"value":"9783319571935","type":"electronic"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-3-319-57193-5_5","type":"book-chapter","created":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T05:03:24Z","timestamp":1499058204000},"page":"129-161","source":"Crossref","is-referenced-by-count":12,"title":["The Complexity of Clinical Huntington\u2019s Disease: Developments in Molecular Genetics, Neuropathology and Neuroimaging Biomarkers"],"prefix":"10.1007","author":[{"given":"Lynette J.","family":"Tippett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry J.","family":"Waldvogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell G.","family":"Snell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Paul","family":"Vonsattel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne B.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard L. M.","family":"Faull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,4]]},"reference":[{"key":"5_CR1","doi-asserted-by":"crossref","unstructured":"Harper PS (1992) The epidemiology of Huntington\u2019s disease. Hum Genet 89(4):365\u2013376","DOI":"10.1007\/BF00194305"},{"issue":"1","key":"5_CR2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1176\/jnp.15.1.109","volume":"15","author":"G Huntington","year":"2003","unstructured":"Huntington G (2003) On chorea (reprinted from the medical and surgical reporter: a weekly journal, vol 26, no. 15, April 13, 1872, pp. 317\u2013321). J Neuropsychiatry Clin Neurosci 15(1):109\u2013112","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"5940","key":"5_CR3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/306234a0","volume":"306","author":"JF Gusella","year":"1983","unstructured":"Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE et al (1983) A polymorphic DNA marker genetically linked to Huntington\u2019s disease. Nature 306(5940):234\u2013238","journal-title":"Nature"},{"issue":"11","key":"5_CR4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/jmg.26.11.673","volume":"26","author":"RG Snell","year":"1989","unstructured":"Snell RG, Lazarou LP, Youngman S, Quarrell OW, Wasmuth JJ, Shaw DJ et al (1989) Linkage disequilibrium in Huntington\u2019s disease: an improved localisation for the gene. J Med Genet 26(11):673\u2013675","journal-title":"J Med Genet"},{"issue":"2","key":"5_CR5","first-page":"357","volume":"51","author":"RG Snell","year":"1992","unstructured":"Snell RG, Thompson LM, Tagle DA, Holloway TL, Barnes G, Harley HG et al (1992) A recombination event that redefines the Huntington disease region. AM J Hum Genet 51(2):357\u2013362","journal-title":"AM J Hum Genet"},{"key":"5_CR6","doi-asserted-by":"crossref","unstructured":"Macdonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L et al (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72(6):971\u2013983","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"5_CR7","doi-asserted-by":"crossref","unstructured":"Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S et al (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 4(4):398\u2013403","DOI":"10.1038\/ng0893-398"},{"key":"5_CR8","doi-asserted-by":"crossref","unstructured":"Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M et al (1993) Trinucleotide repeat length instability and age-of-onset in Huntingtons disease. Nat Genet 4(4):387\u2013392","DOI":"10.1038\/ng0893-387"},{"key":"5_CR9","doi-asserted-by":"crossref","unstructured":"Snell RG, Macmillan JC, Cheadle JP, Fenton I, Lazarou LP, Davies P et al (1993) Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 4(4):393\u2013397","DOI":"10.1038\/ng0893-393"},{"key":"5_CR10","doi-asserted-by":"crossref","unstructured":"Myers RH, Macdonald ME, Koroshetz WJ, Duyao MP, Ambrose CM, Taylor SAM et al (1993) De-novo expansion of a (CAG)(N) repeat in sporadic Huntingtons-disease. Nat Genet 5(2):168\u2013173","DOI":"10.1038\/ng1093-168"},{"issue":"1","key":"5_CR11","first-page":"16","volume":"59","author":"DC Rubinsztein","year":"1996","unstructured":"Rubinsztein DC, Leggo J, Coles R, Almqvist E, Biancalana V, Cassiman JJ et al (1996) Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet 59(1):16\u201322","journal-title":"Am J Hum Genet"},{"key":"5_CR12","unstructured":"Gusella JF, MacDonald ME (2006) Huntington\u2019s disease: seeing the pathogenic process through a genetic lens. Trends Biochem Sci 31(9):533\u2013540"},{"issue":"3","key":"5_CR13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/ajmg.a.20190","volume":"119A","author":"L Djousse","year":"2003","unstructured":"Djousse L, Knowlton B, Hayden M, Almqvist EW, Brinkman R, Ross C et al (2003) Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. Am J Med Genet A 119A(3):279\u2013282","journal-title":"Am J Med Genet A"},{"issue":"10","key":"5_CR14","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1212\/WNL.0b013e318249f683","volume":"78","author":"JM Lee","year":"2012","unstructured":"Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR et al (2012) CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 78(10):690\u2013695","journal-title":"Neurology"},{"key":"5_CR15","doi-asserted-by":"crossref","unstructured":"Keum JW, Shin A, Gillis T, Mysore JS, Abu Elneel K, Lucente D et al (2016) The HTT CAG-expansion mutation determines age at death but not disease duration in Huntington disease. Am J Hum Genet 98(2):287\u2013298","DOI":"10.1016\/j.ajhg.2015.12.018"},{"key":"5_CR16","doi-asserted-by":"crossref","unstructured":"Duyao MP, Auerbach AB, Ryan A, Persichetti F, Barnes GT, McNeil SM et al (1995) Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269(5222):407\u2013410","DOI":"10.1126\/science.7618107"},{"issue":"4","key":"5_CR17","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ng1297-404","volume":"17","author":"JK White","year":"1997","unstructured":"White JK, Auerbach W, Duyao MP, Vonsattel JP, Gusella JF, Joyner AL et al (1997) Huntingtin is required for neurogenesis and is not impaired by the Huntington\u2019s disease CAG expansion. Nat Genet 17(4):404\u2013410","journal-title":"Nat Genet"},{"key":"5_CR18","doi-asserted-by":"crossref","unstructured":"Brook JD, Mccurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H et al (1992) Molecular basis of myotonic dystrophy:\u00a0Expansion of a trinucleotide (CTG) repeat at the 3\u2032 end of a transcript encoding a protein kinase family member. Cell 68(4):799\u2013808","DOI":"10.1016\/0092-8674(92)90154-5"},{"key":"5_CR19","doi-asserted-by":"crossref","unstructured":"Knight SJL, Flannery AV, Hirst MC, Campbell L, Christodoulou Z, Phelps SR et al (1993) Trinucleotide repeat amplification and Hypermethylation of a CpG Island in FRAXE mental retardation. Cell 74(1):127\u2013134","DOI":"10.1016\/0092-8674(93)90300-F"},{"key":"5_CR20","doi-asserted-by":"crossref","unstructured":"Kremer EJ, Pritchard M, Lynch M, Yu S, Holman K, Baker E et al (1991) Mapping of DNA instability at the fragile-X to a trinucleotide repeat sequence p(CCG)n. Science 252(5013):1711\u20131714","DOI":"10.1126\/science.1675488"},{"issue":"6330","key":"5_CR21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/352077a0","volume":"352","author":"AR Spada La","year":"1991","unstructured":"La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352(6330):77\u201379","journal-title":"Nature"},{"key":"5_CR22","doi-asserted-by":"crossref","unstructured":"Koide R, Ikeuchi T, Onodera O, Tanaka H, Igarashi S, Endo K et al (1994) Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet 6(1):9\u201313","DOI":"10.1038\/ng0194-9"},{"key":"5_CR23","doi-asserted-by":"crossref","unstructured":"Orr HT, Chung MY, Banfi S, Kwiatkowski TJ, Servadio A, Beaudet AL et al (1993) Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type-1. Nat Genet 4(3):221\u2013226","DOI":"10.1038\/ng0793-221"},{"issue":"3","key":"5_CR24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ng1196-269","volume":"14","author":"SM Pulst","year":"1996","unstructured":"Pulst SM, Nechiporuk A, Nechiporuk T, Gispert S, Chen XN, LopesCendes I et al (1996) Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 14(3):269\u2013276","journal-title":"Nat Genet"},{"key":"5_CR25","doi-asserted-by":"crossref","unstructured":"Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S et al (1994) CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 8(3):221\u2013228","DOI":"10.1038\/ng1194-221"},{"issue":"1","key":"5_CR26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/ng0197-62","volume":"15","author":"O Zhuchenko","year":"1997","unstructured":"Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C et al (1997) Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha(1A)-voltage-dependent calcium channel. Nat Genet 15(1):62\u201369","journal-title":"Nat Genet"},{"key":"5_CR27","doi-asserted-by":"crossref","unstructured":"Trottier Y, Lutz Y, Stevanin G, Imbert G, Devys D, Cancel G et al (1995) Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 378(6555):403\u2013406","DOI":"10.1038\/378403a0"},{"issue":"11","key":"5_CR28","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/hmg\/8.11.2047","volume":"8","author":"R Koide","year":"1999","unstructured":"Koide R, Kobayashi S, Shimohata T, Ikeuchi T, Maruyama M, Saito M et al (1999) A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? Hum Mol Genet 8(11):2047\u20132053","journal-title":"Hum Mol Genet"},{"issue":"3","key":"5_CR29","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ajhg.2012.01.005","volume":"90","author":"JM Lee","year":"2012","unstructured":"Lee JM, Gillis T, Mysore JS, Ramos EM, Myers RH, Hayden MR et al (2012) Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. Am J Hum Genet 90(3):434\u2013444","journal-title":"Am J Hum Genet"},{"issue":"3","key":"5_CR30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ajhg.2009.02.003","volume":"84","author":"SC Warby","year":"2009","unstructured":"Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H et al (2009) CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet 84(3):351\u2013366","journal-title":"Am J Hum Genet"},{"issue":"3","key":"5_CR31","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1034\/j.1399-0004.2001.600305.x","volume":"60","author":"EW Almqvist","year":"2001","unstructured":"Almqvist EW, Elterman DS, MacLeod PM, Hayden MR (2001) High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia. Clin Genet 60(3):198\u2013205","journal-title":"Clin Genet"},{"issue":"12","key":"5_CR32","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/hmg\/6.12.2005","volume":"6","author":"SE Andrew","year":"1997","unstructured":"Andrew SE, Goldberg YP, Hayden MR (1997) Rethinking genotype and phenotype correlations in polyglutamine expansion disorders. Hum Mol Genet 6(12):2005\u20132010","journal-title":"Hum Mol Genet"},{"key":"5_CR33","doi-asserted-by":"crossref","unstructured":"Goldberg YP, Kremer B, Andrew SE, Theilmann J, Graham RK, Squitieri F et al (1993) Molecular analysis of new mutations for Huntington's disease: intermediate alleles and sex of origin effects. Nat Genet 5(2):174\u2013179","DOI":"10.1038\/ng1093-174"},{"issue":"2","key":"5_CR34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1086\/318193","volume":"68","author":"D Falush","year":"2001","unstructured":"Falush D, Almqvist EW, Brinkmann RR, Iwasa Y, Hayden MR (2001) Measurement of mutational flow implies both a high new-mutation rate for Huntington disease and substantial underascertainment of late-onset cases. Am J Hum Genet 68(2):373\u2013385","journal-title":"Am J Hum Genet"},{"issue":"3","key":"5_CR35","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ajhg.2015.07.017","volume":"97","author":"JM Lee","year":"2015","unstructured":"Lee JM, Kim KH, Shin A, Chao MJ, Abu Elneel K, Gillis T et al (2015) Sequence-level analysis of the major European Huntington disease haplotype. Am J Hum Genet 97(3):435\u2013444","journal-title":"Am J Hum Genet"},{"issue":"5","key":"5_CR36","first-page":"492","volume":"73","author":"JL Li","year":"2003","unstructured":"Li JL, Hayden M, Almqvist EW, Durr A, Dod C, Morrison PJ et al (2003) A genome scan for modifiers of age at onset in Huntington\u2019s disease: the HD MAPS study. Am J Hum Genet 73(5):492","journal-title":"Am J Hum Genet"},{"key":"5_CR37","doi-asserted-by":"crossref","unstructured":"Gusella JF, MacDonald ME, Lee JM (2014) Genetic modifiers of Huntington\u2019s disease. Mov Disord 29(11):1359\u20131365","DOI":"10.1002\/mds.26001"},{"key":"5_CR38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2350-7-71","volume":"7","author":"JL Li","year":"2006","unstructured":"Li JL, Hayden MR, Warby SC, Durr A, Morrison PJ, Nance M et al (2006) Genome-wide significance for a modifier of age at neurological onset in Huntington\u2019s disease at 6q23-24: the HD MAPS study. BMC Med Genet 7:71","journal-title":"BMC Med Genet"},{"key":"5_CR39","doi-asserted-by":"crossref","unstructured":"Gay\u00e1n J, Brocklebank D, Andresen JM, Alkorta-Aranburu G, Cader MZ, Roberts SA et al (2008) Genomewide linkage scan reveals novel loci modifying age of onset of Huntington\u2019s disease in the Venezuelan HD kindreds. Genet Epidemiol 32(5):445\u2013453","DOI":"10.1002\/gepi.20317"},{"issue":"3","key":"5_CR40","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","volume":"162","author":"JM Lee","year":"2015","unstructured":"Lee JM, Wheeler VC, Chao MJ, Vonsattel JPG, Pinto RM, Lucente D et al (2015) Identification of genetic factors that modify clinical onset of Huntington\u2019s disease. Cell 162(3):516\u2013526","journal-title":"Cell"},{"issue":"1","key":"5_CR41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nbd.2008.09.014","volume":"33","author":"E Dragileva","year":"2009","unstructured":"Dragileva E, Hendricks A, Teed A, Gillis T, Lopez ET, Friedberg EC et al (2009) Intergenerational and striatal CAG repeat instability in Huntington\u2019s disease knock-in mice involve different DNA repair genes. Neurobiol Dis 33(1):37\u201347","journal-title":"Neurobiol Dis"},{"key":"5_CR42","doi-asserted-by":"crossref","unstructured":"Pinto RM, Dragileva E, Kirby A, Lloret A, Lopez E, St Claire J et\u00a0al (2013) Mismatch repair genes Mlh1 and Mlh3 modify CAG instability in Huntington\u2019s disease mice: genome-wide and candidate approaches. PLoS Genet 9(10):e1003930","DOI":"10.1371\/journal.pgen.1003930"},{"issue":"5","key":"5_CR43","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","volume":"57","author":"JP Vonsattel","year":"1998","unstructured":"Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57(5):369\u2013384","journal-title":"J Neuropathol Exp Neurol"},{"issue":"12","key":"5_CR44","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/mds.22601","volume":"24","author":"KM Biglan","year":"2009","unstructured":"Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S et al (2009) Motor abnormalities in Premanifest persons with Huntington\u2019s disease: the PREDICT-HD study. Mov Disord 24(12):1763\u20131772","journal-title":"Mov Disord"},{"key":"5_CR45","volume-title":"Movement disorders: neurological principles and practice","author":"F Marshall","year":"2004","unstructured":"Marshall F (2004) Clinical features and treatment of Huntington\u2019s disease. In: Watts R, Koller W (eds) Movement disorders: neurological principles and practice. McGraw-Hill, New York"},{"issue":"2","key":"5_CR46","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1212\/WNL.36.2.244","volume":"36","author":"AB Young","year":"1986","unstructured":"Young AB, Shoulson I, Penney JB, Starosta-Rubinstein S, Gomez F, Travers H et al (1986) Huntington\u2019s disease in Venezuela: neurologic features and functional decline. Neurology 36(2):244\u2013249","journal-title":"Neurology"},{"issue":"7","key":"5_CR47","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1212\/01.wnl.0000204230.16619.d9","volume":"66","author":"A Rosenblatt","year":"2006","unstructured":"Rosenblatt A, Liang KY, Zhou H, Abbott MH, Gourley LM, Margolis RL et al (2006) The association of CAG repeat length with clinical progression in Huntington disease. Neurology 66(7):1016\u20131020","journal-title":"Neurology"},{"issue":"6","key":"5_CR48","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archneur.64.6.813","volume":"64","author":"P Ribai","year":"2007","unstructured":"Ribai P, Nguyen K, Hahn-Barma V, Gourfinkel I, Vidailhet M, Legout A et al (2007) Psychiatric and cognitive difficulties as indicators of juvenile Huntington disease onset in 29 patients. Arch Neurol 64(6):813\u2013819","journal-title":"Arch Neurol"},{"issue":"4","key":"5_CR49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10072-008-0981-7","volume":"29","author":"SH Xing","year":"2008","unstructured":"Xing SH, Chen L, Chen X, Pei Z, Zeng JS, Li JR (2008) Excessive blinking as an initial manifestation of juvenile Huntington\u2019s disease. Neurol Sci 29(4):275\u2013277","journal-title":"Neurol Sci"},{"issue":"12","key":"5_CR50","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1212\/01.WNL.0000098878.47789.BD","volume":"61","author":"AK Ho","year":"2003","unstructured":"Ho AK, Sahakian BJ, Brown RG, Barker RA, Hodges JR, Ane MN et al (2003) Profile of cognitive progression in early Huntington\u2019s disease. Neurology 61(12):1702\u20131706","journal-title":"Neurology"},{"key":"5_CR51","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/brain\/119.5.1633","volume":"119","author":"AD Lawrence","year":"1996","unstructured":"Lawrence AD, Sahakian BJ, Hodges JR, Rosser AE, Lange KW, Robbins TW (1996) Executive and mnemonic functions in early Huntington\u2019s disease. Brain 119:1633\u20131645","journal-title":"Brain"},{"issue":"5","key":"5_CR52","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11910-011-0215-x","volume":"11","author":"JS Paulsen","year":"2011","unstructured":"Paulsen JS (2011) Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep 11(5):474\u2013483","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"5_CR53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1017\/S1355617701711046","volume":"7","author":"J Snowden","year":"2001","unstructured":"Snowden J, Craufurd D, Griffiths H, Thompson J, Neary D (2001) Longitudinal evaluation of cognitive disorder in Huntington\u2019s disease. J Int Neuropsychol Soc 7(1):33\u201344","journal-title":"J Int Neuropsychol Soc"},{"issue":"1","key":"5_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/a0020937","volume":"25","author":"JC Stout","year":"2011","unstructured":"Stout JC, Paulsen JS, Queller S, Solomon AC, Whitlock KB, Campbell JC et al (2011) Neurocognitive signs in prodromal Huntington disease. Neuropsychology 25(1):1\u201314","journal-title":"Neuropsychology"},{"key":"5_CR55","doi-asserted-by":"crossref","unstructured":"Lawrence AD, Hodges JR, Rosser AE, Kershaw A, ffrench-Constant C, Rubinsztein DC et al (1998) Evidence for specific cognitive deficits in preclinical Huntington\u2019s disease. Brain 121:1329\u20131341","DOI":"10.1093\/brain\/121.7.1329"},{"issue":"9","key":"5_CR56","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/mds.22953","volume":"25","author":"GM Peavy","year":"2010","unstructured":"Peavy GM, Jacobson MW, Goldstein JL, Hamilton JM, Kane A, Gamst AC et al (2010) Cognitive and functional decline in Huntington\u2019s disease: dementia criteria revisited. Mov Disord 25(9):1163\u20131169","journal-title":"Mov Disord"},{"issue":"4","key":"5_CR57","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.neuropsychologia.2005.07.003","volume":"44","author":"R Sprengelmeyer","year":"2006","unstructured":"Sprengelmeyer R, Schroeder U, Young AW, Epplen JT (2006) Disgust in pre-clinical Huntington\u2019s disease: a longitudinal study. Neuropsychologia 44(4):518\u2013533","journal-title":"Neuropsychologia"},{"key":"5_CR58","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1093\/brain\/awm107","volume":"130","author":"SA Johnson","year":"2007","unstructured":"Johnson SA, Stout JC, Solomon AC, Langbehn DR, Aylward EH, Cruce CB et al (2007) Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington\u2019s disease. Brain 130:1732\u20131744","journal-title":"Brain"},{"issue":"7","key":"5_CR59","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","volume":"12","author":"SJ Tabrizi","year":"2013","unstructured":"Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA et al (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12(7):637\u2013649","journal-title":"Lancet Neurol"},{"key":"5_CR60","doi-asserted-by":"crossref","unstructured":"Brandt J, Butters N (1986) The neuropsychology of Huntington\u2019s disease. Trends Neurosci:118\u2013120","DOI":"10.1016\/0166-2236(86)90039-1"},{"issue":"1","key":"5_CR61","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1037\/0894-4105.21.1.31","volume":"21","author":"TBR Wahlin","year":"2007","unstructured":"Wahlin TBR, Lundin A, Dear K (2007) Early cognitive deficits in Swedish gene carriers of Huntington\u2019s disease. Neuropsychology 21(1):31\u201344","journal-title":"Neuropsychology"},{"issue":"12","key":"5_CR62","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.biopsych.2006.11.034","volume":"62","author":"K Duff","year":"2007","unstructured":"Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC, Investigators P-H (2007) Psychiatric symptoms in Huntington\u2019s disease before diagnosis: the predict-HD study. Biol Psychiatry 62(12):1341\u20131346","journal-title":"Biol Psychiatry"},{"key":"5_CR63","doi-asserted-by":"crossref","unstructured":"Thompson J, Harris J, Sollom A, Stopford C, Howard E, Snowden J, et al. (2013) Longitudinal evaluation of neuropsychiatric symptoms in Huntington\u2019s disease. J Neuropsychiatry Clin Neurosci 24:53\u201360","DOI":"10.1176\/appi.neuropsych.11030057"},{"issue":"9","key":"5_CR64","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/jnnp.2006.103309","volume":"78","author":"CL Julien","year":"2007","unstructured":"Julien CL, Thompson JC, Wild S, Yardumian P, Snowden JS, Turner G et al (2007) Psychiatric disorders in preclinical Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 78(9):939\u2013943","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"5_CR65","doi-asserted-by":"crossref","first-page":"191","DOI":"10.31887\/DCNS.2007.9.2\/arosenblatt","volume":"9","author":"A Rosenblatt","year":"2007","unstructured":"Rosenblatt A (2007) Neuropsychiatry of Huntington\u2019s disease. Dialogues Clin Neurosci 9(2):191\u2013197","journal-title":"Dialogues Clin Neurosci"},{"issue":"4","key":"5_CR66","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/jnp.2007.19.4.441","volume":"19","author":"E Duijn van","year":"2007","unstructured":"van Duijn E, Kingma EM, van der Mast RC (2007) Psychopathology in verified Huntington\u2019s disease gene carriers. J Neuropsychiatry Clin Neurosci 19(4):441\u2013448","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"5_CR67","first-page":"81","volume":"4","author":"X Du","year":"2013","unstructured":"Du X, Pang TYC, Hannan AJ (2013) A tale of two maladies? Pathogenesis of depression with and without the Huntington\u2019s disease gene mutation. Front Neurol 4:81","journal-title":"Front Neurol"},{"issue":"Pt 4","key":"5_CR68","first-page":"1094","volume":"133","author":"DC Thu","year":"2010","unstructured":"Thu DC, Oorschot DE, Tippett LJ, Nana AL, Hogg VM, Synek BJ et al (2010) Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington\u2019s disease. Brain 133(Pt 4):1094\u20131110","journal-title":"Brain"},{"issue":"Pt 1","key":"5_CR69","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/brain\/awl243","volume":"130","author":"LJ Tippett","year":"2007","unstructured":"Tippett LJ, Waldvogel HJ, Thomas SJ, Hogg VM, van Roon-Mom W, Synek BJ et al (2007) Striosomes and mood dysfunction in Huntington\u2019s disease. Brain 130(Pt 1):206\u2013221","journal-title":"Brain"},{"key":"5_CR70","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/B978-0-12-381328-2.00013-4","volume":"98","author":"MJU Novak","year":"2011","unstructured":"Novak MJU, Tabrizi SJ (2011) Huntington\u2019s disease: clinical presentation and treatment. Int Rev Neurobiol 98:297\u2013323","journal-title":"Int Rev Neurobiol"},{"issue":"8","key":"5_CR71","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/archneur.1995.00540320021009","volume":"52","author":"S Claes","year":"1995","unstructured":"Claes S, van Zand K, Legius E, Dom R, Malfroid M, Baro F et al (1995) Correlations between triplet repeat expansion and clinical features in Huntington\u2019s disease. Arch Neurol 52(8):749\u2013753","journal-title":"Arch Neurol"},{"key":"5_CR72","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fnagi.2013.00012","volume":"5","author":"KM Biglan","year":"2013","unstructured":"Biglan KM, Zhang Y, Long JD, Geschwind M, Kang GA, Killoran A et al (2013) Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front Aging Neurosci 5:12","journal-title":"Front Aging Neurosci"},{"key":"5_CR73","doi-asserted-by":"crossref","unstructured":"Loy CT, McCusker EA (2013) Is a motor criterion essential for the diagnosis of clinical Huntington disease? PLoS Curr 5","DOI":"10.1371\/currents.hd.f4c66bd51e8db11f55e1701af937a419"},{"key":"5_CR74","volume-title":"Huntington\u2019s disease: a disorder of families","author":"SE Folstein","year":"1989","unstructured":"Folstein SE (1989) Huntington\u2019s disease: a disorder of families. John\u2019s Hopkins University Press, Baltimore"},{"issue":"6","key":"5_CR75","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/archneur.1996.00550060035012","volume":"53","author":"B Zappacosta","year":"1996","unstructured":"Zappacosta B, Monza D, Meoni C, Austoni L, Soliveri P, Gellera C et al (1996) Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington\u2019s disease. Arch Neurol 53(6):493\u2013497","journal-title":"Arch Neurol"},{"key":"5_CR76","unstructured":"Tippett L, Hogg V (2015) All in the family: Huntington\u2019s disease, variability and challenges for clinical neuropsychology. In: Macniven JAB (ed) Neuropsychological formulation. Springer, Heidelberg, pp 47\u201370"},{"issue":"1","key":"5_CR77","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ajmg.a.20328","volume":"124A","author":"MH Anca","year":"2004","unstructured":"Anca MH, Gazit E, Loewenthal R, Ostrovsky O, Frydman M, Giladi N (2004) Different phenotypic expression in monozygotic twins with Huntington disease. Am J Med Genet A 124A(1):89\u201391","journal-title":"Am J Med Genet A"},{"issue":"2","key":"5_CR78","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/1531-8257(199903)14:2<320::AID-MDS1018>3.0.CO;2-Z","volume":"14","author":"N Georgiou","year":"1999","unstructured":"Georgiou N, Bradshaw JL, Chiu E, Tudor A, O'Gorman L, Phillips JG (1999) Differential clinical and motor control function in a pair of monozygotic twins with Huntington\u2019s disease. Mov Disord 14(2):320\u2013325","journal-title":"Mov Disord"},{"issue":"1","key":"5_CR79","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000097006","volume":"57","author":"JC Gomez-Esteban","year":"2007","unstructured":"Gomez-Esteban JC, Lezcano E, Zarranz JJ, Velasco F, Garamendi I, Perez T et al (2007) Monozygotic twins suffering from Huntington\u2019s disease show different cognitive and behavioural symptoms. Eur Neurol 57(1):26\u201330","journal-title":"Eur Neurol"},{"issue":"3","key":"5_CR80","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1399-0004.2008.01036.x","volume":"74","author":"M Panas","year":"2008","unstructured":"Panas M, Karadima G, Markianos M, Kalfakis N, Vassilopoulos D (2008) Phenotypic discordance in a pair of monozygotic twins with Huntington\u2019s disease. Clin Genet 74(3):291\u2013292","journal-title":"Clin Genet"},{"key":"5_CR81","doi-asserted-by":"crossref","unstructured":"Macmillan JC, Snell RG, Tyler A, Houlihan GD, Fenton I, Cheadle JP et al (1993) Molecular analysis and clinical correlations of the Huntington's disease mutation. Lancet 342(8877):954\u2013958","DOI":"10.1016\/0140-6736(93)92002-B"},{"issue":"2","key":"5_CR82","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.10094","volume":"51","author":"E Hockly","year":"2002","unstructured":"Hockly E, Cordery PM, Woodman B, Mahal A, van Dellen A, Blakemore C et al (2002) Environmental enrichment slows disease progression in R61\/2 Huntington\u2019s disease mice. Ann Neurol 51(2):235\u2013242","journal-title":"Ann Neurol"},{"issue":"6779","key":"5_CR83","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/35008142","volume":"404","author":"A Dellen van","year":"2000","unstructured":"van Dellen A, Blakemore C, Deacon R, York D, Hannan AJ (2000) Delaying the onset of Huntington\u2019s in mice. Nature 404(6779):721\u2013722","journal-title":"Nature"},{"issue":"10","key":"5_CR84","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/mds.23108","volume":"25","author":"MK Trembath","year":"2010","unstructured":"Trembath MK, Horton ZA, Tippett L, Hogg V, Collins VR, Churchyard A et al (2010) A retrospective study of the impact of lifestyle on age at onset of Huntington disease. Mov Disord 25(10):1444\u20131450","journal-title":"Mov Disord"},{"issue":"2","key":"5_CR85","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/WNL.48.2.394","volume":"48","author":"EH Aylward","year":"1997","unstructured":"Aylward EH, Li Q, Stine OC, Ranen N, Sherr M, Barta PE et al (1997) Longitudinal change in basal ganglia volume in patients with Huntington\u2019s disease. Neurology 48(2):394\u2013399","journal-title":"Neurology"},{"issue":"5","key":"5_CR86","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/00005072-198809000-00003","volume":"47","author":"SM Monte de la","year":"1988","unstructured":"de la Monte SM, Vonsattel JP, Richardson EP Jr (1988) Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington\u2019s disease. J Neuropathol Exp Neurol 47(5):516\u2013525","journal-title":"J Neuropathol Exp Neurol"},{"key":"5_CR87","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0072-9752(07)01256-0","volume":"89","author":"JP Vonsattel","year":"2008","unstructured":"Vonsattel JP, Keller C, Del Pilar Amaya M (2008) Neuropathology of Huntington\u2019s disease. Handb Clin Neurol 89:599\u2013618","journal-title":"Handb Clin Neurol"},{"key":"5_CR88","doi-asserted-by":"crossref","unstructured":"Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP (1985) Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44(6):559\u2013577","DOI":"10.1097\/00005072-198511000-00003"},{"issue":"3","key":"5_CR89","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/brain\/97.1.457","volume":"97","author":"ED Bird","year":"1974","unstructured":"Bird ED, Iversen LL (1974) Huntington\u2019s chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia. Brain 97(3):457\u2013472","journal-title":"Brain"},{"issue":"7812","key":"5_CR90","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(73)90398-X","volume":"1","author":"ED Bird","year":"1973","unstructured":"Bird ED, Mackay AV, Rayner CN, Iversen LL (1973) Reduced glutamic-acid-decarboxylase activity of post-mortem brain in Huntington\u2019s chorea. Lancet 1(7812):1090\u20131092","journal-title":"Lancet"},{"issue":"7","key":"5_CR91","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM197302152880703","volume":"288","author":"TL Perry","year":"1973","unstructured":"Perry TL, Hansen S, Kloster M (1973) Huntington\u2019s chorea. Deficiency of gamma-aminobutyric acid in brain. N Engl J med 288(7):337\u2013342","journal-title":"N Engl J med"},{"key":"5_CR92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1096-9861(19970721)384:1<1::AID-CNE1>3.0.CO;2-5","volume":"384","author":"DJ Holt","year":"1997","unstructured":"Holt DJ, Graybiel AM, Saper CB (1997) Neurochemical architecture of the human striatum. J Comp Neurol 384:1\u201325","journal-title":"J Comp Neurol"},{"key":"5_CR93","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(88)92073-9","volume":"1234","author":"A Seto-Ohshima","year":"1988","unstructured":"Seto-Ohshima A, Emson PC, Lawson E, Mountjoy CQ, Carrasco LH (1988) Loss of matrix calcium-binding protein-containing neurons in Huntington\u2019s disease. Lancet 1234:1252\u20131254","journal-title":"Lancet"},{"issue":"4","key":"5_CR94","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/0306-4522(95)00595-1","volume":"72","author":"SJ Augood","year":"1996","unstructured":"Augood SJ, Faull RL, Love DR, Emson PC (1996) Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington\u2019s disease: a detailed cellular in situ hybridization study. Neuroscience 72(4):1023\u20131036","journal-title":"Neuroscience"},{"key":"5_CR95","doi-asserted-by":"crossref","unstructured":"Marshall PE, Landis DMD, Zalneraitis EL (1983) Immunocytochemical studies of substance-P and leucine-enkephalin in Huntington's disease. Brain Res 289(1\u20132):11\u201326","DOI":"10.1016\/0006-8993(83)90003-3"},{"issue":"3","key":"5_CR96","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jchemneu.2004.02.005","volume":"27","author":"YP Deng","year":"2004","unstructured":"Deng YP, Albin RL, Penney JB, Young AB, Anderson KD, Reiner A (2004) Differential loss of striatal projection systems in Huntington\u2019s disease: a quantitative immunohistochemical study. J Chem Neuroanat 27(3):143\u2013164","journal-title":"J Chem Neuroanat"},{"issue":"3","key":"5_CR97","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","volume":"97","author":"M Glass","year":"2000","unstructured":"Glass M, Dragunow M, Faull RLM (2000) The pattern of neurodegeneration in Huntington\u2019s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington\u2019s disease. Neuroscience 97(3):505\u2013519","journal-title":"Neuroscience"},{"issue":"15","key":"5_CR98","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","volume":"85","author":"A Reiner","year":"1988","unstructured":"Reiner A, Albin RL, Anderson KD, D\u2019Amato CJ, Penney JB, Young AB (1988) Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A 85(15):5733\u20135737","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"5_CR99","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/mds.870110605","volume":"11","author":"F Cicchetti","year":"1996","unstructured":"Cicchetti F, Parent A (1996) Striatal interneurons in Huntington\u2019s disease: selective increase in the density of calretinin-immunoreactive medium-sized neurons. Mov Disord 11(6):619\u2013626","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"5_CR100","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0165-0173(00)00039-4","volume":"34","author":"F Cicchetti","year":"2000","unstructured":"Cicchetti F, Prensa L, Wu Y, Parent A (2000) Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington\u2019s disease. Brain Res Brain Res Rev 34(1\u20132):80\u2013101","journal-title":"Brain Res Brain Res Rev"},{"key":"5_CR101","doi-asserted-by":"crossref","unstructured":"Dawbarn D, Dequidt ME, Emson PC (1985) Survival of basal ganglia neuropeptide Y-somatostatin neurons in Huntington\u2019s disease. Brain Res 340(2):251\u2013260","DOI":"10.1016\/0006-8993(85)90921-7"},{"issue":"1","key":"5_CR102","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00005072-198701000-00002","volume":"46","author":"RJ Ferrante","year":"1987","unstructured":"Ferrante RJ, Kowall NW, Beal MF, Martin JB, Bird ED, Richardson EP Jr (1987) Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington\u2019s disease. J Neuropathol Exp Neurol 46(1):12\u201327","journal-title":"J Neuropathol Exp Neurol"},{"issue":"12","key":"5_CR103","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/mds.25624","volume":"28","author":"A Reiner","year":"2013","unstructured":"Reiner A, Shelby E, Wang HB, DeMarch Z, Deng YP, Guley NH et al (2013) Striatal parvalbuminergic neurons are lost in Huntington\u2019s disease: implications for dystonia. Mov Disord 28(12):1691\u20131699","journal-title":"Mov Disord"},{"issue":"5334","key":"5_CR104","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","volume":"277","author":"M DiFiglia","year":"1997","unstructured":"DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP et al (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277(5334):1990\u20131993","journal-title":"Science"},{"issue":"16","key":"5_CR105","doi-asserted-by":"crossref","first-page":"7688","DOI":"10.1073\/pnas.89.16.7688","volume":"89","author":"LS Dure","year":"1992","unstructured":"Dure LS, Young AB, Penney JB (1992) Compartmentalization of excitatory amino-acid receptors in human striatum. Proc Natl Acad Sci U S A 89(16):7688\u20137692","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5_CR106","doi-asserted-by":"crossref","unstructured":"Graybiel AM, Ragsdale CW, Jr. Histochemically distinct compartments in the striatum of human, monkeys, and cat demonstrated by acetylthiocholinesterase staining. Proc Natl Acad Sci U S A 1978;75(11):5723-5726.","DOI":"10.1073\/pnas.75.11.5723"},{"issue":"3","key":"5_CR107","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/(SICI)1096-9861(19991220)415:3<313::AID-CNE2>3.0.CO;2-7","volume":"415","author":"HJ Waldvogel","year":"1999","unstructured":"Waldvogel HJ, Kubota Y, Fritschy JM, Mohler H, Faull RLM (1999) Regional and cellular localisation of GABA(A) receptor subunits in the human basal ganglia: an autoradiographic and immunohistochemical study. J Comp Neurol 415(3):313\u2013340","journal-title":"J Comp Neurol"},{"issue":"1","key":"5_CR108","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00005072-199501000-00013","volume":"54","author":"JC Hedreen","year":"1995","unstructured":"Hedreen JC, Folstein SE (1995) Early loss of neostriatal striosome neurons in Huntington\u2019s disease. J Neuropathol Exp Neurol 54(1):105\u2013120","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"5_CR109","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0306-4522(93)90294-P","volume":"53","author":"AJ Morton","year":"1993","unstructured":"Morton AJ, Nicholson LF, Faull RL (1993) Compartmental loss of NADPH diaphorase in the neuropil of the human striatum in Huntington\u2019s disease. Neuroscience 53(1):159\u2013168","journal-title":"Neuroscience"},{"key":"5_CR110","doi-asserted-by":"crossref","unstructured":"Faull RL, Waldvogel HJ, Nicholson LF, Synek BJ (1993) The distribution of GABAA-benzodiazepine receptors in the basal ganglia in Huntington\u2019s disease and in the quinolinic acid-lesioned rat. Prog Brain Res 99:105\u2013123","DOI":"10.1016\/S0079-6123(08)61341-2"},{"issue":"2","key":"5_CR111","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1523\/JNEUROSCI.14-02-00599.1994","volume":"14","author":"AW Flaherty","year":"1994","unstructured":"Flaherty AW, Graybiel AM (1994) Input-output organization of the sensorimotor striatum in the squirrel monkey. J Neurosci 14(2):599\u2013610","journal-title":"J Neurosci"},{"issue":"4","key":"5_CR112","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.neuroimage.2006.05.057","volume":"32","author":"G Douaud","year":"2006","unstructured":"Douaud G, Gaura V, Ribeiro MJ, Lethimonnier F, Maroy R, Verny C et al (2006) Distribution of grey matter atrophy in Huntington\u2019s disease patients: a combined ROI-based and voxel-based morphometric study. NeuroImage 32(4):1562\u20131575","journal-title":"NeuroImage"},{"issue":"4","key":"5_CR113","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0022-510X(76)90114-3","volume":"28","author":"H Lange","year":"1976","unstructured":"Lange H, Thorner G, Hopf A, Schroder KF (1976) Morphometric studies of neuropathological changes in choreatic diseases. J Neurol Sci 28(4):401\u2013425","journal-title":"J Neurol Sci"},{"issue":"3","key":"5_CR114","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0306-4522(93)90352-G","volume":"56","author":"M Glass","year":"1993","unstructured":"Glass M, Faull RL, Dragunow M (1993) Loss of cannabinoid receptors in the substantia nigra in Huntington\u2019s disease. Neuroscience 56(3):523\u2013527","journal-title":"Neuroscience"},{"key":"5_CR115","doi-asserted-by":"crossref","unstructured":"Allen KL, Waldvogel HJ, Glass M, Faull RL (2009) Cannabinoid (CB1), GABAA and GABAB receptor subunit changes in the globus pallidus in Huntington\u2019s disease. J Chem Neuroanat 37(4):266\u2013281","DOI":"10.1016\/j.jchemneu.2009.02.001"},{"issue":"12","key":"5_CR116","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/WNL.32.12.1391","volume":"32","author":"JB Penney Jr","year":"1982","unstructured":"Penney JB Jr, Young AB (1982) Quantitative autoradiography of neurotransmitter receptors in Huntington disease. Neurology 32(12):1391\u20131395","journal-title":"Neurology"},{"key":"5_CR117","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ana.410270217","volume":"27","author":"M Cudkowicz","year":"1990","unstructured":"Cudkowicz M, Kowall NW (1990) Degeneration of pyramidal projection neurons in Huntington\u2019s disease cortex. Ann Neurol 27:200\u2013204","journal-title":"Ann Neurol"},{"issue":"2","key":"5_CR118","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0304-3940(91)90583-F","volume":"133","author":"JC Hedreen","year":"1991","unstructured":"Hedreen JC, Peyser CE, Folstein SE, Ross CA (1991) Neuronal loss in layers V and VI of cerebral cortex in Huntington\u2019s disease. Neurosci Lett 133(2):257\u2013261","journal-title":"Neurosci Lett"},{"issue":"3","key":"5_CR119","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1006\/nbdi.2002.0528","volume":"10","author":"V Macdonald","year":"2002","unstructured":"Macdonald V, Halliday G (2002) Pyramidal cell loss in motor cortices in Huntington\u2019s disease. Neurobiol Dis 10(3):378\u2013386","journal-title":"Neurobiol Dis"},{"issue":"6","key":"5_CR120","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-2990.1997.tb01326.x","volume":"23","author":"V Macdonald","year":"1997","unstructured":"Macdonald V, Halliday GM, Trent RJ, McCusker EA (1997) Significant loss of pyramidal neurons in the angular gyrus of patients with Huntington\u2019s disease. Neuropathol Appl Neurobiol 23(6):492\u2013495","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"3","key":"5_CR121","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/archpsyc.55.3.215","volume":"55","author":"G Rajkowska","year":"1998","unstructured":"Rajkowska G, Selemon LD, Goldman-Rakic PS (1998) Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiat 55(3):215\u2013224","journal-title":"Arch Gen Psychiat"},{"issue":"5","key":"5_CR122","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1212\/WNL.58.5.695","volume":"58","author":"HD Rosas","year":"2002","unstructured":"Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, Salat DH et al (2002) Regional and progressive thinning of the cortical ribbon in Huntington\u2019s disease. Neurology 58(5):695\u2013701","journal-title":"Neurology"},{"key":"5_CR123","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1196\/annals.1427.034","volume":"1147","author":"HD Rosas","year":"2008","unstructured":"Rosas HD, Salat DH, Lee SY, Zaleta AK, Hevelone N, Hersch SM (2008) Complexity and heterogeneity: what drives the ever-changing brain in Huntington\u2019s disease? Ann N Y Acad Sci 1147:196\u2013205","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"5_CR124","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1006\/exnr.1998.6919","volume":"154","author":"GM Halliday","year":"1998","unstructured":"Halliday GM, McRitchie DA, Macdonald V, Double KL, Trent RJ, McCusker E (1998) Regional specificity of brain atrophy in Huntington\u2019s disease. Exp Neurol 154(2):663\u2013672","journal-title":"Exp Neurol"},{"issue":"1","key":"5_CR125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/JHD-140092","volume":"3","author":"AL Nana","year":"2014","unstructured":"Nana AL, Kim EH, Thu DC, Oorschot DE, Tippett LJ, Hogg VM et al (2014) Widespread heterogeneous neuronal loss across the cerebral cortex in Huntington\u2019s disease. J Huntingtons Dis 3(1):45\u201364","journal-title":"J Huntingtons Dis"},{"issue":"7","key":"5_CR126","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.41.7.1117","volume":"41","author":"A Sotrel","year":"1991","unstructured":"Sotrel A, Paskevich PA, Kiely DK, Bird ED, Williams RS, Myers RH (1991) Morphometric analysis of the prefrontal cortex in Huntington\u2019s disease. Neurology 41(7):1117\u20131123","journal-title":"Neurology"},{"key":"5_CR127","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1212\/WNL.43.10.2088","volume":"43","author":"A Sotrel","year":"1993","unstructured":"Sotrel A, Williams RS, Kaufmann WE, Myers RH (1993) Evidence for neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of Huntington\u2019s disease: a quantitative Golgi study. Neurology 43:2088\u20132096","journal-title":"Neurology"},{"key":"5_CR128","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-1326-2-8","volume":"2","author":"X Gu","year":"2007","unstructured":"Gu X, Andre VM, Cepeda C, Li SH, Li XJ, Levine MS et al (2007) Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington\u2019s disease. Mol Neurodegener 2:8","journal-title":"Mol Neurodegener"},{"issue":"4","key":"5_CR129","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF00310376","volume":"88","author":"H Heinsen","year":"1994","unstructured":"Heinsen H, Strik M, Bauer M, Luther K, Ulmar G, Gangnus D et al (1994) Cortical and striatal neurone number in Huntington\u2019s disease. Acta Neuropathol 88(4):320\u2013333","journal-title":"Acta Neuropathol"},{"issue":"1","key":"5_CR130","first-page":"21","volume":"31","author":"A Montoya","year":"2006","unstructured":"Montoya A, Price BH, Menear M, Lepage M (2006) Brain imaging and cognitive dysfunctions in Huntington\u2019s disease. J Psychiatry Neurosci 31(1):21\u201329","journal-title":"J Psychiatry Neurosci"},{"issue":"9","key":"5_CR131","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1002\/mds.23747","volume":"26","author":"NZ Hobbs","year":"2011","unstructured":"Hobbs NZ, Pedrick AV, Say MJ, Frost C, Dar Santos R, Coleman A et al (2011) The structural involvement of the cingulate cortex in premanifest and early Huntington\u2019s disease. Mov Disord 26(9):1684\u20131690","journal-title":"Mov Disord"},{"key":"5_CR132","unstructured":"Ferrer I, Kulisevsky J, Gonzalez G, Escartin A, Chivite A, Casas R (1994) Parvalbumin-immunoreactive neurons in the cerebral-cortex and striatum in Huntington's disease. Neurodegeneration 3(2):169\u2013173"},{"issue":"5","key":"5_CR133","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/ana.24162","volume":"75","author":"EH Kim","year":"2014","unstructured":"Kim EH, Thu DCV, Tippett LJ, Oorschot DE, Hogg VM, Roxburgh R et al (2014) Cortical interneuron loss and symptom heterogeneity in Huntington disease. Ann Neurol 75(5):717\u2013727","journal-title":"Ann Neurol"},{"issue":"6","key":"5_CR134","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/cercor\/bhh185","volume":"15","author":"J Kassubek","year":"2005","unstructured":"Kassubek J, Juengling FD, Ecker D, Landwehrmeyer GB (2005) Thalamic atrophy in Huntington\u2019s disease co-varies with cognitive performance: a morphometric MRI analysis. Cereb Cortex 15(6):846\u2013853","journal-title":"Cereb Cortex"},{"issue":"6","key":"5_CR135","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s004010051037","volume":"97","author":"H Heinsen","year":"1999","unstructured":"Heinsen H, Rub U, Bauer M, Ulmar G, Bethke B, Schuler M et al (1999) Nerve cell loss in the thalamic mediodorsal nucleus in Huntington\u2019s disease. Acta Neuropathol 97(6):613\u2013622","journal-title":"Acta Neuropathol"},{"key":"5_CR136","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.nbd.2013.08.009","volume":"60","author":"YP Deng","year":"2013","unstructured":"Deng YP, Wong T, Bricker-Anthony C, Deng B, Reiner A (2013) Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington\u2019s disease mice. Neurobiol Dis 60:89\u2013107","journal-title":"Neurobiol Dis"},{"issue":"44","key":"5_CR137","doi-asserted-by":"crossref","first-page":"14610","DOI":"10.1523\/JNEUROSCI.1623-10.2010","volume":"30","author":"NM Doig","year":"2010","unstructured":"Doig NM, Moss J, Bolam JP (2010) Cortical and thalamic innervation of direct and indirect pathway medium-sized spiny neurons in mouse striatum. J Neurosci 30(44):14610\u201314618","journal-title":"J Neurosci"},{"issue":"1","key":"5_CR138","first-page":"117","volume":"36","author":"D Wamelen van","year":"2013","unstructured":"van Wamelen D, Aziz N, Anink J, van Steenhoven R, Angeloni D, Fraschini F et al (2013) Suprachiasmatic nucleus neuropeptide expression in patients with Huntington\u2019s disease. Sleep 36(1):117\u2013125","journal-title":"Sleep"},{"issue":"4","key":"5_CR139","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1750-3639.2008.00135.x","volume":"18","author":"A Aziz","year":"2008","unstructured":"Aziz A, Fronczek R, Maat-Schieman M, Unmehopa U, Roelandse F, Overeem S et al (2008) Hypocretin and melanin-concentrating hormone in patients with Huntington disease. Brain Pathol 18(4):474\u2013483","journal-title":"Brain Pathol"},{"issue":"10","key":"5_CR140","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2174\/1389450111007011237","volume":"11","author":"S Hult","year":"2010","unstructured":"Hult S, Schultz K, Soylu R, Petersen A (2010) Hypothalamic and neuroendocrine changes in Huntington\u2019s disease. Curr Drug Targets 11(10):1237\u20131249","journal-title":"Curr Drug Targets"},{"issue":"1","key":"5_CR141","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1523\/JNEUROSCI.3842-04.2005","volume":"25","author":"AJ Morton","year":"2005","unstructured":"Morton AJ, Wood NI, Hastings MH, Hurelbrink C, Barker RA, Maywood ES (2005) Disintegration of the sleep-wake cycle and circadian timing in Huntington\u2019s disease. J Neurosci 25(1):157\u2013163","journal-title":"J Neurosci"},{"issue":"1","key":"5_CR142","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/hmg\/ddi004","volume":"14","author":"A Petersen","year":"2005","unstructured":"Petersen A, Gil J, Maat-Schieman ML, Bjorkqvist M, Tanila H, Araujo IM et al (2005) Orexin loss in Huntington\u2019s disease. Hum Mol Genet 14(1):39\u201347","journal-title":"Hum Mol Genet"},{"issue":"1","key":"5_CR143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/exnr.1998.7006","volume":"157","author":"A Petersen","year":"1999","unstructured":"Petersen A, Mani K, Brundin P (1999) Recent advances on the pathogenesis of Huntington\u2019s disease. Exp Neurol 157(1):1\u201318","journal-title":"Exp Neurol"},{"issue":"4","key":"5_CR144","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00005072-199007000-00002","volume":"49","author":"HP Kremer","year":"1990","unstructured":"Kremer HP, Roos RA, Dingjan G, Marani E, Bots GT (1990) Atrophy of the hypothalamic lateral tuberal nucleus in Huntington\u2019s disease. J Neuropathol Exp Neurol 49(4):371\u2013382","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"5_CR145","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0304-3940(91)90443-W","volume":"132","author":"HP Kremer","year":"1991","unstructured":"Kremer HP, Roos RA, Dingjan GM, Bots GT, Bruyn GW, Hofman MA (1991) The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington\u2019s disease. Neurosci Lett 132(1):101\u2013104","journal-title":"Neurosci Lett"},{"issue":"5","key":"5_CR146","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/jnnp.56.5.487","volume":"56","author":"E Spargo","year":"1993","unstructured":"Spargo E, Everall IP, Lantos PL (1993) Neuronal loss in the hippocampus in Huntington\u2019s disease: a comparison with HIV infection. J Neurol Neurosurg Psychiatry 56(5):487\u2013491","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5_CR147","unstructured":"Fourie C, Kim E, Waldvogel H, Wong J, Faull R, McGregor A et al (2014) Differential changes in postsynaptic density proteins in post-mortem Huntington\u2019s disease and Parkinson\u2019s disease human brains. J Neurodegener Dis 2014:938530"},{"issue":"10","key":"5_CR148","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1212\/01.WNL.0000065888.88988.6E","volume":"60","author":"HD Rosas","year":"2003","unstructured":"Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME et al (2003) Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 60(10):1615\u20131620","journal-title":"Neurology"},{"issue":"1\u20132","key":"5_CR149","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jns.2011.05.015","volume":"307","author":"SJA Bogaard van den","year":"2011","unstructured":"van den Bogaard SJA, Dumas EM, Ferrarini L, Milles J, van Buchem MA, van der Grond J et\u00a0al (2011) Shape analysis of subcortical nuclei in Huntington\u2019s disease, global versus local atrophy\u00a0\u2013 results from the TRACK-HD study. J Neurol Sci 307(1\u20132):60\u201368","journal-title":"J Neurol Sci"},{"issue":"2","key":"5_CR150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1750-3639.2012.00629.x","volume":"23","author":"U R\u00fcb","year":"2013","unstructured":"R\u00fcb U, Hoche F, Brunt ER, Heinsen H, Seidel K, Del Turco D et al (2013) Degeneration of the cerebellum in Huntington\u2019s disease (HD): possible relevance for the clinical picture and potential gateway to pathological mechanisms of the disease process. Brain Pathol 23(2):165\u2013177","journal-title":"Brain Pathol"},{"issue":"11","key":"5_CR151","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/mds.26013","volume":"29","author":"EH Aylward","year":"2014","unstructured":"Aylward EH (2014) Magnetic resonance imaging striatal volumes: a biomarker for clinical trials in Huntington\u2019s disease. Mov Disord 29(11):1429\u20131433","journal-title":"Mov Disord"},{"issue":"3","key":"5_CR152","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.neubiorev.2013.01.022","volume":"37","author":"N Georgiou-Karistianis","year":"2013","unstructured":"Georgiou-Karistianis N, Scahill R, Tabrizi SJ, Squitieri F, Aylward E (2013) Structural MRI in Huntington\u2019s disease and recommendations for its potential use in clinical trials. Neurosci Biobehav Rev 37(3):480\u2013490","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"5_CR153","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH et al (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10(4):204\u2013216","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"5_CR154","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(11)70070-9","volume":"10","author":"DW Weir","year":"2011","unstructured":"Weir DW, Sturrock A, Leavitt BR (2011) Development of biomarkers for Huntington\u2019s disease. Lancet Neurol 10(6):573\u2013590","journal-title":"Lancet Neurol"},{"issue":"4","key":"5_CR155","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.2010.208264","volume":"82","author":"EH Aylward","year":"2011","unstructured":"Aylward EH, Nopoulos PC, Ross CA, Langbehn DR, Pierson RK, Mills JA et al (2011) Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 82(4):405\u2013410","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3\u20134","key":"5_CR156","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.brainresbull.2010.04.003","volume":"82","author":"JS Paulsen","year":"2010","unstructured":"Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA et al (2010) Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull 82(3\u20134):201\u2013207","journal-title":"Brain Res Bull"},{"issue":"3","key":"5_CR157","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/1531-8257(200005)15:3<552::AID-MDS1020>3.0.CO;2-P","volume":"15","author":"EH Aylward","year":"2000","unstructured":"Aylward EH, Codori AM, Rosenblatt A, Sherr M, Brandt J, Stine OC et al (2000) Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington\u2019s disease. Mov Disord 15(3):552\u2013560","journal-title":"Mov Disord"},{"key":"5_CR158","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/brain\/122.9.1667","volume":"122","author":"GJ Harris","year":"1999","unstructured":"Harris GJ, Codori AM, Lewis RF, Schmidt E, Bedi A, Brandt J (1999) Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington\u2019s disease. Brain 122:1667\u20131678","journal-title":"Brain"},{"issue":"14","key":"5_CR159","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/mds.23912","volume":"26","author":"DSA Majid","year":"2011","unstructured":"Majid DSA, Aron AR, Thompson W, Sheldon S, Hamza S, Stoffers D et al (2011) Basal ganglia atrophy in prodromal Huntington\u2019s disease is detectable over one year using automated segmentation. Mov Disord 26(14):2544\u20132551","journal-title":"Mov Disord"},{"issue":"9","key":"5_CR160","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","volume":"8","author":"SJ Tabrizi","year":"2009","unstructured":"Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RAC, Durr A, Craufurd D et al (2009) Biological and clinical manifestations of Huntington\u2019s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8(9):791\u2013801","journal-title":"Lancet Neurol"},{"key":"5_CR161","doi-asserted-by":"crossref","unstructured":"Harris GJ, Pearlson GD, Peyser CE, Aylward EH, Roberts J, Barta PE et al (1992) Putamen volume reduction on magnetic-resonance-imaging exceeds caudate changes in mild Huntington\u2019s disease. Ann Neurol 31(1):69\u201375","DOI":"10.1002\/ana.410310113"},{"issue":"9","key":"5_CR162","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.biopsych.2011.07.030","volume":"71","author":"EH Aylward","year":"2012","unstructured":"Aylward EH, Liu DW, Nopoulos PC, Ross CA, Pierson RK, Mills JA et al (2012) Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biol Psychiatry 71(9):822\u2013828","journal-title":"Biol Psychiatry"},{"issue":"1","key":"5_CR163","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00415-009-0086-0","volume":"256","author":"W Vandenberghe","year":"2009","unstructured":"Vandenberghe W, Demaerel P, Dom R, Maes F (2009) Diffusion-weighted versus volumetric imaging of the striatum in early symptomatic Huntington disease. J Neurol 256(1):109\u2013114","journal-title":"J Neurol"},{"key":"5_CR164","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fnagi.2014.00078","volume":"6","author":"JS Paulsen","year":"2014","unstructured":"Paulsen JS, Long JD, Johnson HJ, Aylward EH, Ross CA, Williams JK et al (2014) Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study. Front Aging Neurosci 6:78","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"5_CR165","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","volume":"11","author":"SJ Tabrizi","year":"2012","unstructured":"Tabrizi SJ, Reilmann R, Roos RAC, Durr A, Leavitt B, Owen G et al (2012) Potential endpoints for clinical trials in premanifest and early Huntington\u2019s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 11(1):42\u201353","journal-title":"Lancet Neurol"},{"issue":"5","key":"5_CR166","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1017\/S1355617798455061","volume":"4","author":"JR Campodonico","year":"1998","unstructured":"Campodonico JR, Aylward E, Codori AM, Young C, Krafft L, Magdalinski M et al (1998) When does Huntington\u2019s disease begin? J Int Neuropsychol Soc 4(5):467\u2013473","journal-title":"J Int Neuropsychol Soc"},{"issue":"11","key":"5_CR167","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00415-008-0050-4","volume":"255","author":"CK Jurgens","year":"2008","unstructured":"Jurgens CK, van de Wiel L, van Es ACGM, Grimbergen YM, Witjes-Ane MNW, van der Grond J et\u00a0al (2008) Basal ganglia volume and clinical correlates in \u2018preclinical\u2019 Huntington\u2019s disease. J Neurol 255(11):1785\u20131791","journal-title":"J Neurol"},{"issue":"3","key":"5_CR168","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/hbm.21449","volume":"34","author":"RI Scahill","year":"2013","unstructured":"Scahill RI, Hobbs NZ, Say MJ, Bechtel N, Henley SMD, Hyare H et al (2013) Clinical impairment in premanifest and early Huntington\u2019s disease is associated with regionally specific atrophy. Hum Brain Mapp 34(3):519\u2013529","journal-title":"Hum Brain Mapp"},{"issue":"3","key":"5_CR169","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.nbd.2010.07.014","volume":"40","author":"PC Nopoulos","year":"2010","unstructured":"Nopoulos PC, Aylward EH, Ross CA, Johnson HJ, Magnotta VA, Juhl AR et al (2010) Cerebral cortex structure in prodromal Huntington disease. Neurobiol Dis 40(3):544\u2013554","journal-title":"Neurobiol Dis"},{"issue":"1","key":"5_CR170","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1212\/WNL.50.1.252","volume":"50","author":"EH Aylward","year":"1998","unstructured":"Aylward EH, Anderson NB, Bylsma FW, Wagster MV, Barta PE, Sherr M et al (1998) Frontal lobe volume in patients with Huntington\u2019s disease. Neurology 50(1):252\u2013258","journal-title":"Neurology"},{"issue":"7","key":"5_CR171","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/jnnp.2009.190702","volume":"81","author":"NZ Hobbs","year":"2010","unstructured":"Hobbs NZ, Henley SMD, Ridgway GR, Wild EJ, Barker RA, Scahill RI et al (2010) The progression of regional atrophy in premanifest and early Huntington\u2019s disease: a longitudinal voxel-based morphometry study. J Neurol Neurosurg Psychiatry 81(7):756\u2013763","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5_CR172","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/brain\/awf179","volume":"125","author":"MJ Thieben","year":"2002","unstructured":"Thieben MJ, Duggins AJ, Good CD, Gomes L, Mahant N, Richards F et al (2002) The distribution of structural neuropathology in pre-clinical Huntington\u2019s disease. Brain 125:1815\u20131828","journal-title":"Brain"},{"issue":"5","key":"5_CR173","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/jnnp.2004.047993","volume":"76","author":"CM Kipps","year":"2005","unstructured":"Kipps CM, Duggins AJ, Mahant N, Gomes L, Ashburner J, McCusker EA (2005) Progression of structural neuropathology in preclinical Huntington\u2019s disease: a tensor based morphometry study. J Neurol Neurosurg Psychiatry 76(5):650\u2013655","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"20","key":"5_CR174","doi-asserted-by":"crossref","first-page":"11050","DOI":"10.1073\/pnas.200033797","volume":"97","author":"B Fischl","year":"2000","unstructured":"Fischl B, Dale AM (2000) Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A 97(20):11050\u201311055","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"5_CR175","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1212\/01.wnl.0000174432.87383.87","volume":"65","author":"HD Rosas","year":"2005","unstructured":"Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B (2005) Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 65(5):745\u2013747","journal-title":"Neurology"},{"issue":"Pt 4","key":"5_CR176","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/brain\/awn025","volume":"131","author":"HD Rosas","year":"2008","unstructured":"Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B et al (2008) Cerebral cortex and the clinical expression of Huntington\u2019s disease: complexity and heterogeneity. Brain 131(Pt 4):1057\u20131068","journal-title":"Brain"},{"issue":"9","key":"5_CR177","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/mds.23762","volume":"26","author":"HD Rosas","year":"2011","unstructured":"Rosas HD, Reuter M, Doros G, Lee SY, Triggs T, Malarick K et al (2011) A tale of two factors: what determines the rate of progression in Huntington\u2019s disease? A longitudinal MRI study. Mov Disord 26(9):1691\u20131697","journal-title":"Mov Disord"},{"key":"5_CR178","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.neuroimage.2013.05.007","volume":"83","author":"J Jovicich","year":"2013","unstructured":"Jovicich J, Marizzoni M, Sala-Llonch R, Bosch B, Bartres-Faz D, Arnold J et\u00a0al (2013) Brain morphometry reproducibility in multi-center 3 T MRI studies: a comparison of cross-sectional and longitudinal segmentations. NeuroImage 83:472\u2013484","journal-title":"NeuroImage"},{"issue":"4","key":"5_CR179","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.neuroimage.2012.02.084","volume":"61","author":"M Reuter","year":"2012","unstructured":"Reuter M, Schmansky NJ, Rosas HD, Fischl B (2012) Within-subject template estimation for unbiased longitudinal image analysis. NeuroImage 61(4):1402\u20131418","journal-title":"NeuroImage"},{"issue":"4","key":"5_CR180","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3233\/JHD-130077","volume":"2","author":"HE Crawford","year":"2013","unstructured":"Crawford HE, Hobbs NZ, Keogh R, Langbehn DR, Frost C, Johnson H et al (2013) Corpus callosal atrophy in premanifest and early Huntington\u2019s disease. J Huntingtons Dis 2(4):517\u2013526","journal-title":"J Huntingtons Dis"},{"issue":"6","key":"5_CR181","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1212\/01.WNL.0000138434.68093.67","volume":"63","author":"C Fennema-Notestine","year":"2004","unstructured":"Fennema-Notestine C, Archibald SL, Jacobson MW, Corey-Bloom J, Paulsen JS, Peavy GM et al (2004) In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology 63(6):989\u2013995","journal-title":"Neurology"},{"issue":"4","key":"5_CR182","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1016\/j.neuroimage.2009.10.015","volume":"49","author":"HD Rosas","year":"2010","unstructured":"Rosas HD, Lee SY, Bender AC, Zaleta AK, Vangel M, Yu P et al (2010) Altered white matter microstructure in the corpus callosum in Huntington\u2019s disease: implications for cortical \u201cdisconnection\u201d. NeuroImage 49(4):2995\u20133004","journal-title":"NeuroImage"},{"issue":"9","key":"5_CR183","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/mds.20979","volume":"21","author":"HD Rosas","year":"2006","unstructured":"Rosas HD, Tuch DS, Hevelone ND, Zaleta AK, Vangel M, Hersch SM et al (2006) Diffusion tensor imaging in presymptomatic and early Huntington\u2019s disease: selective white matter pathology and its relationship to clinical measures. Mov Disord 21(9):1317\u20131325","journal-title":"Mov Disord"},{"issue":"3","key":"5_CR184","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/jnnp.2007.142786","volume":"81","author":"A Sritharan","year":"2010","unstructured":"Sritharan A, Egan GF, Johnston L, Horne M, Bradshaw JL, Bohanna I et al (2010) A longitudinal diffusion tensor imaging study in symptomatic Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 81(3):257\u2013262","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"5_CR185","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/hbm.21205","volume":"33","author":"EM Dumas","year":"2012","unstructured":"Dumas EM, van den Bogaard SJA, Ruber ME, Reilman RR, Stout JC, Craufurd D et al (2012) Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington\u2019s disease. Hum Brain Mapp 33(1):203\u2013212","journal-title":"Hum Brain Mapp"},{"key":"5_CR186","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cortex.2013.11.009","volume":"52","author":"MJU Novak","year":"2014","unstructured":"Novak MJU, Seunarine KK, Gibbard CR, Hobbs NZ, Scahill RI, Clark CA et al (2014) White matter integrity in premanifest and early Huntington\u2019s disease is related to caudate loss and disease progression. Cortex 52:98\u2013112","journal-title":"Cortex"},{"key":"5_CR187","doi-asserted-by":"crossref","unstructured":"Kl\u00f6ppel S, Draganski B, Golding CV, Chu C, Nagy Z, Cook PA et al (2008) White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington\u2019s disease. Brain 131:196\u2013204","DOI":"10.1093\/brain\/awm275"},{"issue":"9","key":"5_CR188","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1017\/S003329171300247X","volume":"44","author":"R Sprengelmeyer","year":"2014","unstructured":"Sprengelmeyer R, Orth M, Muller HP, Wolf RC, Gron G, Depping MS et al (2014) The neuroanatomy of subthreshold depressive symptoms in Huntington\u2019s disease: a combined diffusion tensor imaging (DTI) and voxel-based morphometry (VBM) study. Psychol Med 44(9):1867\u20131878","journal-title":"Psychol Med"},{"key":"5_CR189","doi-asserted-by":"crossref","unstructured":"Gregory S, Scahill RI, Seunarine KK, Stopford C, Zhang H, Zhang J et\u00a0al (2015) Neuropsychiatry and white matter microstructure in Huntington\u2019s disease. J Huntington\u2019s Dis 4(3):239\u2013249","DOI":"10.3233\/JHD-150160"},{"issue":"4","key":"5_CR190","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1212\/WNL.32.4.354","volume":"32","author":"TL Perry","year":"1982","unstructured":"Perry TL, Wright JM, Hansen S, Thomas SMB, Allan BM, Baird PA et al (1982) A double-blind clinical-trial of isoniazid in Huntington disease. Neurology 32(4):354\u2013358","journal-title":"Neurology"},{"issue":"1","key":"5_CR191","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.34.1.94","volume":"34","author":"G Scigliano","year":"1984","unstructured":"Scigliano G, Giovannini P, Girotti F, Grassi MP, Caraceni T, Schechter PJ (1984) Gamma-vinyl GABA treatment of Huntington\u2019s disease. Neurology 34(1):94\u201396","journal-title":"Neurology"},{"issue":"5","key":"5_CR192","first-page":"545","volume":"3","author":"D Paleacu","year":"2007","unstructured":"Paleacu D (2007) Tetrabenazine in the treatment of Huntington\u2019s disease. Neuropsychiatr Dis Treat 3(5):545\u2013551","journal-title":"Neuropsychiatr Dis Treat"},{"key":"5_CR193","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejphar.2015.10.033","volume":"769","author":"S Jamwal","year":"2015","unstructured":"Jamwal S, Kumar P (2015) Antidepressants for neuroprotection in Huntington\u2019s disease: a review. Eur J Pharmacol 769:33\u201342","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"5_CR194","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3171\/2014.2.JNS131722","volume":"121","author":"V Gonzalez","year":"2014","unstructured":"Gonzalez V, Cif L, Biolsi B, Garcia-Ptacek S, Seychelles A, Sanrey E et al (2014) Deep brain stimulation for Huntington\u2019s disease: long-term results of a prospective open-label study. J Neurosurg 121(1):114\u2013122","journal-title":"J Neurosurg"},{"issue":"10","key":"5_CR195","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrn3570","volume":"14","author":"MA Pouladi","year":"2013","unstructured":"Pouladi MA, Morton AJ, Hayden MR (2013) Choosing an animal model for the study of Huntington\u2019s disease. Nat rev Neurosci 14(10):708\u2013721","journal-title":"Nat rev Neurosci"},{"issue":"5","key":"5_CR196","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","volume":"22","author":"RJ Ferrante","year":"2002","unstructured":"Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM et al (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington\u2019s disease. J Neurosci 22(5):1592\u20131599","journal-title":"J Neurosci"},{"issue":"12","key":"5_CR197","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1523\/JNEUROSCI.20-12-04389.2000","volume":"20","author":"RJ Ferrante","year":"2000","unstructured":"Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK et al (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington\u2019s disease. J Neurosci 20(12):4389\u20134397","journal-title":"J Neurosci"},{"issue":"10","key":"5_CR198","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1212\/WNL.0000000000000187","volume":"82","author":"HD Rosas","year":"2014","unstructured":"Rosas HD, Doros G, Gevorkian S, Malarick K, Reuter M, Coutu JP et al (2014) PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology 82(10):850\u2013857","journal-title":"Neurology"},{"issue":"30","key":"5_CR199","doi-asserted-by":"crossref","first-page":"12483","DOI":"10.1073\/pnas.0904239106","volume":"106","author":"F Cicchetti","year":"2009","unstructured":"Cicchetti F, Saporta S, Hauser RA, Parent M, Saint-Pierre M, Sanberg PR et al (2009) Neural transplants in patients with Huntington\u2019s disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci U S A 106(30):12483\u201312488","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"5_CR200","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1602\/neurorx.1.4.394","volume":"1","author":"SB Dunnett","year":"2004","unstructured":"Dunnett SB, Rosser AE (2004) Cell therapy in Huntington\u2019s disease. NeuroRx 1(4):394\u2013405","journal-title":"NeuroRx"},{"issue":"4","key":"5_CR201","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrm2873","volume":"11","author":"P Brundin","year":"2010","unstructured":"Brundin P, Melki R, Kopito R (2010) Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Bio 11(4):301\u2013307","journal-title":"Nat Rev Mol Cell Bio"},{"issue":"1","key":"5_CR202","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ana.24174","volume":"76","author":"F Cicchetti","year":"2014","unstructured":"Cicchetti F, Lacroix S, Cisbani G, Vallieres N, Saint-Pierre M, St-Amour I et al (2014) Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol 76(1):31\u201342","journal-title":"Ann Neurol"},{"issue":"1","key":"5_CR203","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/cge.12385","volume":"86","author":"C Kay","year":"2014","unstructured":"Kay C, Skotte NH, Southwell AL, Hayden MR (2014) Personalized gene silencing therapeutics for Huntington disease. Clin Genet 86(1):29\u201336","journal-title":"Clin Genet"},{"issue":"16","key":"5_CR204","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","volume":"102","author":"SQ Harper","year":"2005","unstructured":"Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q et al (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model. Proc Natl Acad Sci U S A 102(16):5820\u20135825","journal-title":"Proc Natl Acad Sci U S A"}],"updated-by":[{"DOI":"10.1007\/978-3-319-57193-5_21","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T00:00:00Z","timestamp":1505260800000}}],"container-title":["Advances in Neurobiology","Neurodegenerative Diseases"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-57193-5_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T01:36:20Z","timestamp":1719279380000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-57193-5_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9783319571911","9783319571935"],"references-count":204,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-57193-5_5","relation":{},"ISSN":["2190-5215","2190-5223"],"issn-type":[{"value":"2190-5215","type":"print"},{"value":"2190-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}